The Orchestra Study will examine an investigational medication called UCB0599 in patients with early-stage Parkinson’s disease .
It will include patients with Parkinson’s disease (newly diagnosed or early-stage disease) from several countries across North America and Europe. As it is assessing disease and symptom progression over a long period of time, the Orchestra Study can only recruit patients with early-stage Parkinson’s disease (diagnosed within the last 2 years) who show mild symptoms.
The study could last up to 21 months for every participant. Participants will be randomly assigned (like drawing straws) to receive either the study drug or placebo; they will have an equal chance (50%) of receiving either the study drug or a placebo (a placebo looks like the study drug but contains no medicinally active ingredients). The study drug or placebo is given orally (by mouth) twice a day every day for 18 months.
Participation in the Orchestra Study will include visits at the study site with the study doctor and study team, as well as optional home visits. Home visits enable the study team to continue monitoring the participant's health and well-being while limiting the number of trips to the study site. A research nurse will visit the participant's home to carry out the required tests and procedures while the participant speaks to the study doctor and his or her team over video.
If you want to find out if you may qualify to participate in the study, please visit the study pre-screener webpage: https://orchestra.researchstudytrial.com.